GSK gained rights to a Hutchmed antibody-targeted therapy conjugate, or ATTC. This new type of targeted therapy blocks two cancer-driving proteins and will initially be developed for lung, colorectal, and pancreatic cancers.
The Hutchmed drug, fruquintinib, is already approved in China for colorectal cancer. Takeda Pharmaceutical gets global rights to the small molecule, which has started a rolling submission with the FDA and is being readied for regulatory submissions in Europe and Japan.
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.